Who are Resuscitation (Voluven)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): succinylated gelatin injection, HES 130/0.42 + electrolyte solution, balanced 6% hydroxyethylstarch 130/0.4, HES 10%, Hydroxyethylstarch 6% 130/0.4, Gelofusine balanced.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/resuscitation-voluven.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Resuscitation (Voluven) — Competitive Intelligence Brief

Resuscitation (Voluven) (Resuscitation (Voluven)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colloid plasma volume expander. Area: Critical Care / Emergency Medicine.

phase 3 Colloid plasma volume expander Critical Care / Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Resuscitation (Voluven) (Resuscitation (Voluven)) — Universidad Nacional de La Plata. Voluven is a hydroxyethyl starch (HES) plasma volume expander that increases and maintains circulating blood volume in patients with acute blood loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Resuscitation (Voluven) TARGET	Resuscitation (Voluven)	Universidad Nacional de La Plata	phase 3	Colloid plasma volume expander
succinylated gelatin injection	succinylated gelatin injection	Nanjing Chia-tai Tianqing Pharmaceutical	marketed	Colloid plasma volume expander
HES 130/0.42 + electrolyte solution	HES 130/0.42 + electrolyte solution	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
balanced 6% hydroxyethylstarch 130/0.4	balanced 6% hydroxyethylstarch 130/0.4	University Hospital Muenster	marketed	Synthetic colloid plasma volume expander
HES 10%	HES 10%	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
Hydroxyethylstarch 6% 130/0.4	Hydroxyethylstarch 6% 130/0.4	Medical University of Vienna	marketed	Synthetic colloid plasma volume expander
Gelofusine balanced	Gelofusine balanced	B. Braun Melsungen AG	phase 3	Colloid plasma volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colloid plasma volume expander class)

B. Braun Melsungen AG · 1 drug in this class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class
Universidad Nacional de La Plata · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Resuscitation (Voluven) — Competitive Intelligence Brief. https://druglandscape.com/ci/resuscitation-voluven. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab